![4,10-Dioxatri cyclo[5.2. 1.02.6]dec-8-ene-3,5-dione (7-Oxanorborna-2-ene-5,6-dicarboxylic anhydride)](/upload/1124/V75907.png)
| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
As a purine nucleoside analog, this compound primarily targets the DNA synthesis machinery. It is hypothesized to be incorporated into replicating DNA, where it acts as an antimetabolite. The general mechanism for this class of compounds involves competition with natural purine nucleosides, leading to the disruption of DNA replication, inhibition of cell proliferation, and the induction of cell death in rapidly dividing cells like cancer cells.
|
|---|---|
| ln Vitro |
In vitro, this compound is used as a research tool for studying the effects of nucleoside analogs on cell growth. It is predicted to exhibit antiproliferative activity against a range of cancer cell lines, particularly those derived from indolent lymphoid malignancies. Its specific IC50 values are not reported in the provided literature, but its activity is inferred from its classification as a purine nucleoside analog.
|
| ln Vivo |
In vivo, this compound is intended for research use. Based on its classification, it is expected to have broad antitumor activity. However, detailed in vivo efficacy data for this specific compound is not available in the provided literature. It is primarily a chemical tool or building block for synthesis rather than a well-characterized pharmacological agent in animal models.
|
| Enzyme Assay |
Cell-free assays for this compound are not described. Given its classification, an in vitro DNA polymerase assay could be used. This would involve incubating a DNA polymerase with a DNA template, a mixture of natural deoxynucleotide triphosphates (dNTPs), and the compound (likely as a triphosphate derivative). The ability of the analog to be incorporated into DNA or inhibit the enzyme would then be measured.
|
| Cell Assay |
Cellular assays for evaluating its activity would follow a standard protocol for nucleoside analogs. Cancer cell lines (e.g., lymphoma or leukemia cells) are seeded in 96-well plates and treated with serial dilutions of the compound (e.g., from 0.1 uM to 100 uM) for 48-72 hours. Cell viability is measured using an MTT or CellTiter-Glo assay to determine an IC50 value. Induction of apoptosis can be confirmed by flow cytometry using Annexin V staining.
|
| Animal Protocol |
Specific in vivo animal study protocols for this compound are not provided. A general protocol for testing antitumor activity would involve using immunocompromised mice bearing xenografts of human cancer cell lines. The compound, formulated in a suitable vehicle, would be administered intraperitoneally (IP) or orally (p.o.) at various dose levels. Tumor growth would be measured to determine its in vivo efficacy, but such data is not currently available.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for this compound is not available. However, as a purine nucleoside analog, its properties are likely defined by its solubility and potential for cellular uptake via nucleoside transporters. It is soluble in DMSO at ≥ 100 mg/mL, allowing for stock solution preparation. It is stable as a powder for up to 3 years at -20degC, but clinical development has not been reported.
|
| Toxicity/Toxicokinetics |
Toxicology data for this specific compound is not provided. As a purine nucleoside analog with potential DNA synthesis inhibitory activity, it could be cytotoxic to rapidly dividing cells. However, without detailed in vivo studies, its specific safety profile is not characterized. In research use, standard laboratory safety precautions (e.g., handling as a potential carcinogen) are recommended. It has no reported clinical use.
|
| References |
[1]. Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88.
|
| Additional Infomation |
structure
This compound is a synthetic purine nucleoside analog. One of its key features is its Diels-Alder adduct structure, which can be synthesized from maleic anhydride and furan. It is used primarily as a building block in organic synthesis or as a tool in epigenetic research. It is not a drug candidate that has advanced to clinical trials. Its value lies in its unique rigid structure, which can be used to probe the binding pockets of enzymes involved in DNA replication and repair. |
| Molecular Formula |
C8H6O4
|
|---|---|
| Molecular Weight |
166.13
|
| Exact Mass |
166.026
|
| CAS # |
5426-09-5
|
| PubChem CID |
98484
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
372.0±42.0 °C at 760 mmHg
|
| Flash Point |
172.2±27.9 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.584
|
| LogP |
-0.77
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
12
|
| Complexity |
278
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1OC(C2C(O3)C=CC3C21)=O
|
| InChi Key |
QQYNRBAAQFZCLF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H6O4/c9-7-5-3-1-2-4(11-3)6(5)8(10)12-7/h1-6H
|
| Chemical Name |
4,10-dioxatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0194 mL | 30.0969 mL | 60.1938 mL | |
| 5 mM | 1.2039 mL | 6.0194 mL | 12.0388 mL | |
| 10 mM | 0.6019 mL | 3.0097 mL | 6.0194 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
